News and Media
Immunicom has achieved considerable momentum through major clinical trials and regulatory milestones. It has an exceptional story to tell in immune-oncology through receiving FDA Breakthrough Designation, European approval (CE Mark) for metastatic TNBC, and raft of promising data across its global clinical trials for multiple indications including some that are unmet medical needs.
View our latest news and media
Press Releases
Publications
Featured News
Videos
Awards
Media Kit
Press Releases
June 14, 2022
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
June 2, 2022
Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
April 28, 2022
Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
April 12, 2022
Immunicom Announces Addition of Key Industry Leaders to Board of Directors
Publications & Abstracts
May 9, 2023
ESMO Breast Cancer 2023
April 14, 2023
AACR Annual Meeting 2023
June 2, 2022
ASCO Annual Meeting 2022
April 18, 2022
AACR Annual Meeting 2022
December 3, 2021
Journal for Immunotherapy of Cancer
September 14, 2021
1st JCA-AACR Precision Cancer Medicine International Conference
July 20, 2021
Journal of Clinical Oncology, An American Society of Clinical Oncology Journal
June 10, 2021
AACR Journal of Cancer Research Proceedings
January 1, 2021
White Paper – Immunopheresis® Technology Overview
February 10, 2020
Journal of Clinical Oncology, An American Society of Clinical Oncology Journal
December 31, 2018
Journal of Translational Medicine: “Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic”
Featured News
December 15, 2022
Longevity Technology – Innovative cancer treatment device has longevity potential
December 15, 2022
Oncology Tube: The LW-02 Cartridge
November 9, 2022
Empowered Patient Podcast with Karen Jagoda -Treating Tumors Using Subtractive Approach to Remove Molecules Suppressing Immune System with Amir Jafri Immunicom
December 1, 2020
StartUpCity’s Global “Ten Most Promising 2020 Biotech Startups”
July 9, 2020
Jerusalem Post – Sheba Launches World’s First ‘Reversed Personalized Medicine’ Cancer Trial
Videos & Presentations
Immunicom Introduction
Immunicom Corporate Commercial
Immunopheresis® Treatment Overview
New Frontier in Immuno-Therapies Webinar
CEO Amir Jafri Presents at LSI Emerging Medtech Conference
JCA-AACR 2021 Abstract Presentation
Zoomtopia Healthcare Innovation Award
Recognitions & Awards
Milestones
June 2022
NCI/NIH Awards $2M to Immunicom to initiate clinical trial at Baylor College of Medicine to treat refractory ER+/Her2- breast cancer
November 2021
Terumo BCT and Immunicom establish limited commercialization agreement
September 2021
Start of pre-clinical trials for the EN-06 cartridge, the second product of the Immunopheresis® therapy platform
October 2020
First patient enrolled in multi-arm clinical trial at Acibadem Healthcare Group hospitals to evaluate Immunopheresis® for non-small cell lung cancer in combination with Roche’s pharmaceutical checkpoint inhibitor, Tecentriq®
July 2020
First patient enrolled in clinical trial at Sheba Medical Center to investigate the outcomes of Immunopheresis® as a monotherapy and combination therapy. The trial is assessing metastatic melanoma, TNBC, renal cell carcinoma and non-small cell lung cancer
May 2020
The Immunopheresis® LW-02 cartridge received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory TNBC
July 2019
Immunicom hosted the first Annual Global Immunopheresis Conference in Krakow, Poland
June 2019
First patient enrolled in multi-center clinical trial at University of Krakow to investigate the outcomes of Immunopheresis® as a treatment for patients with TNBC
August 2018
Immunicom leaders co-authored peer reviewed article in The Journal of Translational Medicine on unleashing TNF-alpha as a cancer immunotherapeutic
May 2018
The U.S. FDA awards Immunicom Breakthrough Device Designation for the treatment of cancer
December 2017
University of California San Diego and Immunicom entered an exclusive licensing agreement to co-develop targeted molecule delivery technology
February 2016
End of pre-clinical canine trail, achieving 300 Immunopheresis® treatments. Overall, 50-60% of the canine patients treated were observed to have either a stable disease or partial response and one canine experienced a complete response with clearance of metastases.
December 2015
Completed $5.5M Series a Preferred Stock financing
May 2014
Start of pre-clinical canine trial
January 2014
Immunicom enters into a strategic partnership with Terumo BCT, an industry leading manufacturer of therapeutic apheresis equipment
2013
Founded by Amir Jafri
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team